Page last updated: 2024-11-05

chlorproguanil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

chlorproguanil: dichloro-derivative of chloroguanide; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9571037
CHEMBL ID1213553
CHEBI ID135192
SCHEMBL ID44783
SCHEMBL ID19745866
MeSH IDM0049950

Synonyms (34)

Synonym
CHEMBL1213553
chlorproguanil
imidodicarbonimidic diamide, n-(3,4-dichlorophenyl)-n'-(1-methylethyl)-
1-(3,4-dichlorophenyl)-3-(n-isopropylcarbamimidoyl)guanidine
biguanide, 1-(3,4-dichoro-phenyl)-5-isopropyl-
537-21-3
n-(3,4-dichlorophenyl)-n'-(1-methylethyl)imidodicarbonimidic diamide
einecs 208-660-3
clorpreguanile [dcit]
chlorproguanilum [inn-latin]
1-(3,4-dichlorophenyl)-5-isopropylbiguanide
chlorproguanil [inn:ban]
clorproguanil [inn-spanish]
CHEBI:135192
8o3249m729 ,
clorproguanil
clorpreguanile
chlorproguanilum
unii-8o3249m729
M-5943 ,
m 5943
n1-3,4-dichlorophenyl-n5-isopropyldiguanide
SCHEMBL44783
biguanide, 1-(3,4-dichlorophenyl)-5-isopropyl-
chlorproguanil [inn]
proguanil hydrochloride impurity f [ep impurity]
chlorproguanil [who-dd]
n1-3,4-dichlorophenyl-n5-isopropylbiguanide
chlorproguanil [mi]
ISZNZKHCRKXXAU-UHFFFAOYSA-N
n-(3,4-dichlorophenyl)-n'-isopropyldicarbonimido/ic diamide/imido #
DTXSID5022807
DB12314
SCHEMBL19745866

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The no or low adverse effect levels were in the range of 5 to 7 mg/kg/day artesunate."( Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit.
A Clode, S; Clark, RL; Gaunt, I; Ward, SA; White, TE; Winstanley, P, 2004
)
0.32

Pharmacokinetics

Plasmodium falciparum malaria has no effect on the pharmacokinetic parameters for chlorproguanil, dapsone or chlorcycloguanil.

ExcerptReferenceRelevance
"The pharmacokinetic parameters of chlorproguanil (Lapudrine) and its active metabolite, chlorcycloguanil, were determined in 6 healthy male volunteers after a single oral dose of 4 Lapudrine tables (80 mg)."( Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine.
Edstein, MD; Rieckmann, KH; Veenendaal, JR, 1988
)
0.27
"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00."( Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.
Aarons, L; Bojang, K; Edwards, G; Hughes, D; Manyando, C; Simpson, JA; Ward, S; Watkins, WA; Winstanley, P, 2006
)
0.33
"Plasmodium falciparum malaria has no effect on the pharmacokinetic parameters for chlorproguanil, dapsone or chlorcycloguanil."( Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.
Aarons, L; Bojang, K; Edwards, G; Hughes, D; Manyando, C; Simpson, JA; Ward, S; Watkins, WA; Winstanley, P, 2006
)
0.33
" Blood samples for pharmacokinetic analysis were collected up to 24 h post-first dose."( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009
)
0.35
"The pharmacokinetic analysis included 115 patients."( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The potency of antimalarial dihydrofolate reductase inhibitors, alone and in synergistic combination with dihydropteroate synthetase inhibitors, against the Kenyan K39 strain of Plasmodium falciparum (pyrimethamine resistant) and against normal replicating human bone marrow cells in in vitro culture has been studied."( In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.
Breckenridge, AM; Mberu, EK; Szwandt, IS; Watkins, WM; Winstanley, PA, 1995
)
0.29
" Further studies are now required to determine whether DDS, CPG or an as-yet unidentified metabolite of CPG interact with ASN, and whether a simple double combination of ASN with one or other of these would be as protective, against the selection of resistance, as CDA."( The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate.
Peters, W; Robinson, BL; Stewart, LB, 2005
)
0.33

Dosage Studied

Rats were dosed orally with chlorproguanil/dapsone/artesunate (including 11. subjects) In 2 of 10 subjects dosed with proguanil and 1 of 11 subjects dose with chlor ProguAnil, active metabolite levels were significantly lower than the mean for the other subjects.

ExcerptRelevanceReference
" carinii in vitro, a clinical trial of reduced dosage of dapsone given prophylactically to human beings is suggested."( Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model.
González-Ruiz, A; Haworth, SJ; O'Neil, AB; Warhurst, DC, 1991
)
0.28
" In 2 of 10 subjects dosed with proguanil and 1 of 11 subjects dosed with chlorproguanil, the active metabolite levels were significantly lower than the mean for the other subjects."( A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.
Chulay, JD; Howells, RE; Sixsmith, DG; Spencer, HC; Watkins, WM, 1987
)
0.27
" Using the '4-day test', a low level of synergism or a simple additional action between CPG and DDS was observed with multiple dosing of these two compounds in a combination."( The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate.
Peters, W; Robinson, BL; Stewart, LB, 2005
)
0.33
" For CCG and MADDS, small to moderate increases in exposure with artesunate dosing were observed."( Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
Bandyopadhyay, N; Duparc, S; Kirby, PL; Miller, AK; Ward, SA; Winstanley, PA; Wootton, DG, 2009
)
0.35
"Rats were dosed orally with chlorproguanil/dapsone/artesunate (including 11."( Localization of artesunate and its derivatives in the pregnant rat and fetus following oral administration and relationship to developmental toxicity.
Clark, RL; Gristwood, WE; Harrell, AW; Lewsley, R; Wilson, R, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1688330Antimalarial activity against Plasmodium falciparum by radioisotopic method2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (24.19)18.7374
1990's14 (22.58)18.2507
2000's28 (45.16)29.6817
2010's4 (6.45)24.3611
2020's1 (1.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (30.00%)5.53%
Reviews6 (8.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (61.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan [NCT00158561]Phase 3750 participants Interventional2004-02-29Completed
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children [NCT00393679]Phase 34,112 participants (Actual)Interventional2007-07-31Completed
Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs [NCT00158574]Phase 2/Phase 32,419 participants (Actual)Interventional2005-01-31Completed
A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adoles [NCT00344006]Phase 31,395 participants (Actual)Interventional2006-06-30Completed
An Open, Randomised, Multi-centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate [NCT00519467]Phase 2120 participants (Actual)Interventional2003-06-30Completed
Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children [NCT00461578]800 participants Interventional2005-04-30Completed
Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings [NCT00118794]Phase 31,200 participants Interventional2004-09-30Completed
Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment [NCT00126971]Phase 1132 participants Interventional2005-07-31Suspended
Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya [NCT00111163]1,516 participants Interventional2004-03-31Completed
A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults [NCT00371735]Phase 3900 participants (Actual)Interventional2006-04-30Completed
Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania [NCT00146731]Phase 3310 participants (Actual)Interventional2004-01-31Completed
A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi [NCT00164359]Phase 4212 participants Interventional2005-04-30Completed
An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi [NCT00164710]Phase 4365 participants Interventional2005-04-30Completed
Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants. [NCT00361114]Phase 3112 participants (Actual)Interventional2006-07-31Terminated(stopped due to SP arms were stopped due to high levels of treatment failure.CD not available.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]